Neuraxpharm rebrands Laboratorios Lesvi as Neuraxpharm Pharmaceuticals S.L.

Press release


Press Release | Version in English
Nota de Prensa | Versión en Español

Neuraxpharm rebrands Laboratorios Lesvi as Neuraxpharm Pharmaceuticals S.L.

Share on twitter
Share on linkedin
Share on facebook

Laboratorios Lesvi is Neuraxpharm’s manufacturing facility for Finished Dosage Forms (FDF) in Spain


Barcelona and Dusseldorf – May 4, 2023 – Neuraxpharm Group (Neuraxpharm), the leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, announces that it has rebranded Laboratorios Lesvi to create Neuraxpharm Pharmaceuticals S.L.

Laboratorios Lesvi S.L. in Sant Joan Despí, near Barcelona, Spain, is one of two manufacturing plants owned and operated by Neuraxpharm. Established in 1979, Laboratorios Lesvi was originally part of Invent Farma, a group of Spanish companies which were merged with Neuraxpharm Germany in 2016. Laboratorios Lesvi employs more than 280 people developing and manufacturing finished dosage forms (FDFs) for the Group and for other national and global pharmaceutical companies. Focusing on solid oral dosage forms, over the last six years the site has grown by 56% (by units produced) and invested around EUR 30 million to consolidate this outstanding growth, adapting its facilities to adopt the newest and highest quality standards for production and ESG in the industry.

Burghard Burczyk, Chief Technology Officer of Neuraxpharm, said: “The rebranding of this important part of Neuraxpharm’s production capacity to form Neuraxpharm Pharmaceuticals S.L. marks its full integration within the Group. Our ability to develop and manufacture top quality products is essential, and we are proud to have an established business able to deliver this for the Group and more widely.” 

As the leading European specialty pharmaceutical company focused on treating CNS disorders, Neuraxpharm continues to make significant progress across geographies and product areas. In February of this year, Neuraxpharm completed the acquisition from Sanofi of two established portfolios of mainly CNS products consisting of 17 molecules representing 38 brands in more than 50 countries worldwide. Last year, Neuraxpharm expanded its portfolio by entering the medical devices and digital health area as well as completing a strategic license agreement for its first orphan CNS indication. Furthermore, during 2022, Neuraxpharm expanded its business in Greece and the Netherlands before completing its presence in the Benelux early this year through the establishment of Neuraxpharm Belgium to cover Belgium and Luxembourg.

These recent developments further solidify Neuraxpharm’s position as a leader in the treatment of CNS disorders, increasing the company’s global footprint and business.